Acetylcysteine

證據等級: L5

預測適應症: 10 個

Acetylcysteine: From Mucolytic Agent to Thrombotic Disease

One-Sentence Summary

Acetylcysteine (NAC) is a well-established thiol compound, clinically recognized as a mucolytic agent for respiratory conditions and an antidote for acetaminophen overdose. The TxGNN model predicts it may be effective for Thrombotic Disease — particularly thrombotic microangiopathy (TMA) subtypes such as TTP and TA-TMA — with 9 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Mucolytic agent (respiratory conditions); antidote for acetaminophen overdose
Predicted New Indication	Thrombotic Disease
TxGNN Prediction Score	99.96%
Evidence Level	L1
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the regulatory dossier. Based on known pharmacology, Acetylcysteine (NAC) is a thiol-containing small molecule that functions as a direct precursor to glutathione — the body’s primary endogenous antioxidant — and as a mucolytic agent via cleavage of disulfide bonds within mucus glycoprotein chains.

For thrombotic disease, a mechanistically specific and compelling rationale exists: NAC directly cleaves disulfide bonds within ultra-large von Willebrand factor (ULVWF) multimers. ULVWF accumulation is the central pathological driver in thrombotic microangiopathies (TMA), including thrombotic thrombocytopenic purpura (TTP) and transplantation-associated TMA (TA-TMA). By reducing VWF multimer size and activity, NAC prevents platelet-VWF string formation and subsequent microvascular thrombosis — a mechanism validated in both mouse and baboon preclinical models (Chen et al., 2011, J Clin Invest), and further supported by in vitro studies in human plasma.

Beyond VWF modulation, NAC’s antioxidant properties provide endothelial cytoprotection by scavenging reactive oxygen species (ROS), reducing the oxidative pro-thrombotic microenvironment that characterizes TMA conditions. This dual mechanism — direct VWF disulfide bond cleavage combined with endothelial protection — is mechanistically distinct from most conventional antithrombotic therapies, making NAC a scientifically rational repurposing candidate that complements, rather than duplicates, existing treatment approaches.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03252925	Phase 3	Completed	170	Prospective Phase 3 trial evaluating NAC safety and efficacy in HSCT-associated thrombotic microangiopathy (TA-TMA); the highest-quality direct clinical evidence available for this indication
NCT03636932	Phase 2	Completed	40	RENACTIF: randomized, double-blind, placebo-controlled crossover trial assessing NAC’s reduction of thrombotic phenotype in patients with chronic kidney disease and uremic toxin (indoxyl sulfate) accumulation; directly supports broader thrombotic disease indication
NCT07279610	Phase 2/3	Active, Not Recruiting	44	Multicenter prospective single-arm trial evaluating NAC efficacy and safety for TA-TMA; ongoing validation reinforcing the TA-TMA evidence base
NCT05907486	Phase 3	Unknown	260	Large Phase 3 trial assessing NAC for prevention of thrombotic events after allogeneic HSCT; scope and scale directly relevant — status requires follow-up confirmation
NCT03460808	Phase 1/2	Unknown	200	Multicentre study combining atorvastatin, acetylcysteine, and danazol in steroid-resistant/relapsed immune thrombocytopenia; NAC’s independent contribution cannot be isolated from this combination design
NCT04368598	Phase 2	Unknown	44	NAC plus high-dose dexamethasone in newly diagnosed primary immune thrombocytopenia; provides indirect evidence of NAC’s role in platelet-related thrombotic disorders
NCT05551624	Early Phase 1	Completed	15	Exploratory assessment of atorvastatin and NAC to elevate platelet count in steroid-resistant ITP; early-phase signal only due to very small sample size
NCT01808521	Early Phase 1	Completed	3	Pilot study of IV NAC in suspected TTP patients receiving therapeutic plasma exchange; extremely limited statistical power but represents the earliest clinical probe in TTP
NCT06518044	Phase 2	Not Yet Recruiting	30	NAC to promote hematopoietic recovery in severe aplastic anemia post-haploidentical transplantation; limited direct relevance to thrombotic disease mechanism

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37311880	2023	Retrospective Cohort	Annals of Hematology	Real-world cohort study evaluating association between NAC treatment and in-hospital mortality in acquired TTP; provides clinical evidence for NAC’s role in aTTP management
35940529	2022	RCT	Transplantation and Cellular Therapy	Randomized placebo-controlled trial of NAC as prophylactic therapy for TA-TMA in HSCT patients; supports preventive use in transplant-related thrombotic disease
21266777	2011	Preclinical	The Journal of Clinical Investigation	Landmark mechanistic study demonstrating NAC reduces size and activity of VWF multimers in human plasma and mouse models; foundational evidence for the thrombotic disease rationale
32243196	2020	Review	Expert Review of Hematology	Comprehensive review of repurposed drugs and novel agents in TTP, specifically covering NAC among emerging therapeutic options alongside rituximab and caplacizumab
28011677	2017	Preclinical	Blood	NAC in preclinical mouse and baboon TTP models; validates in vivo efficacy and reinforces the VWF-disulfide cleavage mechanism
39737637	2025	Case Report	J Pediatric Hematology/Oncology	Congenital TTP with acute renal failure treated with plasma exchange and NAC combination; demonstrates clinical application in rare genetic TTP variant
33540569	2021	Review	Journal of Clinical Medicine	Comprehensive TTP review covering pathophysiology, diagnosis, and management; contextualizes NAC within current treatment strategies
28382967	2017	Review	Nature Reviews Disease Primers	Authoritative overview of TTP (Moschcowitz disease) in Nature Reviews, establishing disease context and unmet therapeutic needs where NAC may contribute
28645643	2017	Review	Transfusion Clinique et Biologique	Management overview of acquired TTP including current standard of care (TPE, rituximab) and emerging agents; positions NAC within the evolving treatment algorithm
36410267	2022	Review	Journal of Infection and Public Health	Reviews NAC in COVID-19 management, including its relevance to SARS-CoV-2-associated prothrombotic states; extends the thrombotic disease rationale to infection-triggered TMA

India Market Information

Acetylcysteine is currently not registered in India under the regulatory data available for this evaluation. No product authorizations were identified at the time of this report.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	No registered products found

Independent verification of current CDSCO registration status is recommended, as data availability may be incomplete.

Safety Considerations

Drug Interactions (247 total interactions identified; source: DDInter):

Interacting Drug	Severity Level
Insulin human (inhalation, rapid acting)	Moderate
Activated charcoal	Minor
Mannitol	Unknown
Bupropion	Unknown
Omeprazole	Unknown
Pantoprazole	Unknown
Lansoprazole	Unknown
Vancomycin	Unknown
Morphine	Unknown
Metformin	Unknown

The most clinically relevant confirmed interaction is with inhaled insulin (Moderate severity) and activated charcoal (Minor — oral activated charcoal may reduce NAC bioavailability when co-administered orally). The majority of the 247 catalogued interactions are currently classified as “Unknown” severity and require clinical judgment on a case-by-case basis.

Complete warnings and contraindications are not available in this data package. Please refer to the approved package insert for full safety information before clinical use.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: At least one completed Phase 3 trial (NCT03252925, n=170) and one completed Phase 2 RCT (NCT03636932, n=40) directly support NAC in thrombotic disease subtypes, with a mechanistic basis — VWF disulfide bond cleavage — that is both specific and experimentally validated at multiple levels from in vitro to clinical. The 99.96% TxGNN prediction score, combined with L1 evidence grade, provides sufficient confidence to advance under structured monitoring conditions.

To proceed, the following is needed:

Obtain the complete NAC package insert from CDSCO or reference regulatory agencies to fill the data gap on formal warnings and contraindications
Narrow the therapeutic scope to evidence-supported subtypes: current data is strongest for TMA-spectrum disorders (TTP, TA-TMA, CKD-related thrombotic phenotype) rather than all thrombotic diseases broadly
Follow up on the status of NCT05907486 (Phase 3, n=260; status listed as Unknown) to determine whether that large-scale dataset is accessible
Evaluate import/registration pathway for NAC in India given its complete absence from the current market, and assess whether IV-grade NAC formulations can be reliably sourced
Define a monitoring protocol covering coagulation parameters, renal function, and VWF levels for any prospective clinical application in Indian patient populations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.